AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.

Trial Details

NCT ID
NCT05211570
Phase
PHASE1 / PHASE2
Sponsor
AB Science
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • AB8939
  • Venetoclax
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327
  • Marseille, France|43.29695,5.38107
  • Athens, Greece|37.98376,23.72784
  • Alicante, Spain|38.34517,-0.48149
  • Cáceres, Spain|39.47649,-6.37224

Key Eligibility Criteria

  • Patients with documented diagnosis of acute myeloid leukemia (AML) based on the last version of the World Health Organization classification and el…
  • Patients with documented diagnosis of refractory melyodisplastic syndrome in second or third line of treatment, and with high risk at prognosis bas…
  • ECOG performance status ≤ 1
  • Patients are able to understand, sign, and date the written informed consent form at screening visit prior to any protocol-specific procedures

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →